Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up for clinical development, and spinning them into startups, gathers pace. At the same time, Nodus Oncology Ltd., the first spinout created around an acquired asset, has just reached in vivo proof of concept with its lead DNA damage response inhibitor, and it, too, is looking to raise a series A to take the program through to the end of phase I. Read More
During a webinar arranged by Demy-Colton, panelists discussed a wide range of potential outcomes that might occur depending on which political party ends up in power next year. From tweaks to the Inflation Reduction Act to new laws to the Federal Trade Commission's regulation of M&As, there’s potential for the government to have substantial effects on the drug development industry. Read More
Since the publication of The Hallmarks of Aging in 2013, aging research has exploded. The field now has more than 300,000 articles on the biological signals of the effect of time on the body. What would Marty McFly, the legendary character from the Back to the Future saga who traveled with his DeLorean time machine from the ‘80s to the ‘50s, think if he visited 2024 and saw laboratories experimenting with techniques to turn back the biological clocks of cells or increase the lifespan of rejuvenated mice? Read More
Navigator Medicines Inc. is charting a course through the autoimmune disease drug landscape, having raised $100 million in a series A funding round to advance an OX40 ligand (OX40L)-targeted portfolio licensed from South Korea’s Imbiologics Corp. Read More
Yoltech Therapeutics Co. Ltd. licensed its PCSK9-targeting gene editing therapeutic, YOLT-101, to Shenzhen Salubris Pharmaceuticals Co. Ltd. for mainland China rights in a deal worth ¥1.035 billion (US$145 million). Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arcutis, Krystal, Neurocrine, Novartis, Nxera, Shilpa Medicare. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bayer, Flagship Pioneering, Foundation Medicine, Genentech, Merus, Nextrna, Pfizer, Polyrizon, Quotient, Regeneron, Roche, Scisparc, Zuellig. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astellas, GSK, Springworks, Telix. Read More
